REDWOOD CITY, Calif., May 1, 2015 AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Timothy E. Morris, chief financial officer will be participating in three upcoming investor events. Details of the events are as follows:
Mizuho Third Annual Healthcare Corporate Access Day
Date: Tuesday, May 5
Location: The Omni Berkshire Place, New York
Bank of America Healthcare Conference 2015
Date: Tuesday, May 12
Location: Encore at the Wynn, Las Vegas
Presentation Time: 12 pm PT, 3 pm ET
UBS Global Healthcare Conference
Date: Monday, May 18
Location: Sheraton Times Square Hotel, New York
The Bank of America conference presentation will be webcast live and can be accessed through the Investors page at www.acelrx.com. For those not available to listen to the live broadcast, a replay will be archived for 90 days and available through the Investors page on www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, Zalviso, is designed for the management of moderate-to-severe acute pain in adult patients in the hospital setting by utilizing a high therapeutic index opioid, through a non-invasive delivery route via a pre-programmed, patient-controlled analgesia device. AcelRx has announced positive results from each of the three completed Phase 3 clinical trials for Zalviso, and has submitted an NDA to the FDA seeking approval for Zalviso in the treatment of moderate-to-severe acute pain in adult patients in the hospital setting and on July 25, 2014, received a Complete Response Letter from the FDA. AcelRx received correspondence from the FDA stating that in addition to the bench testing and two Human Factors studies AcelRx has performed, an additional clinical study is needed to assess the risk of inadvertent dispensing and overall risk of dispensing failures. AcelRx plans to meet with the FDA to discuss and understand the need and potential objectives of an additional clinical study for Zalviso. AcelRx has initiated a Phase 3 clinical trial for ARX-04, a product candidate for the treatment of moderate-to-severe acute pain in a medically supervised setting.
For additional information about AcelRx's clinical programs, please visit www.acelrx.com.
Logo - http://photos.prnewswire.com/prnh/20130226/MM67303LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-participate-at-upcoming-investor-conferences-in-may-300075433.html
SOURCE AcelRx Pharmaceuticals, Inc.
Timothy E. Morris, Chief Financial Officer, 650.216.3511, email@example.com, Brian Korb, The Trout Group LLC, 646.378.2923, firstname.lastname@example.org